SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new patient-reported
outcomes data for olorinab, an investigational, oral, peripherally
acting, highly-selective, full agonist of the cannabinoid receptor
2 (CB2) in development for the treatment of visceral
pain associated with gastrointestinal (GI) disorders, at the
European Society of Neurogastroenterology & Motility (ESNM)
2019 NeuroGASTRO Meeting.
"We were pleased to see that overall, patient-reported outcomes
across all domains evaluated improved at 8 weeks compared to
baseline in our Phase 2a study of olorinab. Our ultimate goal with
the olorinab program is to improve the quality of life for patients
suffering from abdominal pain associated with GI disorders, and
these results are encouraging," stated Dr. Preston Klassen, Executive Vice President, Head
of Research & Development at Arena. "We look forward to seeing
additional data from our Phase 2b
CAPTIVATE trial which we expect to read out in the second half of
2020."
Presentation Details:
Title: Development of
Olorinab, a Cannabinoid Type 2 Receptor Agonist, for the Management
of Chronic Abdominal Pain Disorders
Abstract number: 226
Abstract Category: Visceral pain mechanisms
About Arena Pharmaceuticals
Arena Pharmaceuticals is
driven to deliver novel, transformational medicines with optimized
pharmacology to patients globally. Arena's proprietary pipeline
includes multiple potentially first- or best-in-class assets with
broad clinical utility. Etrasimod (APD334), with potential
utility in a broad range of immune and inflammatory conditions, is
being evaluated in later-stage clinical programs in ulcerative
colitis (UC) and Crohn's disease (CD), as well as in programs for
other indications such as atopic dermatitis. Arena is also
evaluating olorinab (APD371) in a Phase 2 program for
gastrointestinal pain. Arena continues to assess other earlier
research and development stage drug candidates, including APD418
for decompensated heart failure.
Arena has additional license agreements and partnerships,
including with United Therapeutics (ralinepag in a Phase 3 program
for pulmonary arterial hypertension), Everest Medicines Limited
(etrasimod in Greater China and
select Asian countries), Boehringer Ingelheim International GmbH
(undisclosed target – preclinical), Outpost Medicine, LLC
(undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai
Inc. (BELVIQ® – marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These forward-looking statements may be
identified by introductory words such as "in development for,"
"goal," "look forward to," "expect," "will," "objective," "driven
to," "potentially," "potential," "evaluating," or words of similar
meaning, or by the fact that they do not relate strictly to
historical or current facts. Such forward-looking statements
include, without limitation, statements regarding Arena's goals for
the olorinab program; Arena's CAPTIVATE study, including its
objectives, enrollment, and the timing of data readout; Arena's
drive; and the potential of Arena's assets, programs, licenses, and
partnerships. For such statements, Arena claims the protection of
the Private Securities Litigation Reform Act of 1995. Actual events
or results may differ materially from Arena's expectations. Factors
that could cause actual results to differ materially from the
forward-looking statements include, without limitation, the
following: the announced data may not accurately reflect the final
results of the CAPTIVATE study; results of clinical trials and
other studies are subject to different interpretations and may not
be predictive of future results; nonclinical and clinical data are
voluminous and detailed, and regulatory agencies may interpret or
weigh the importance of data differently and reach different
conclusions than Arena or others, request additional information,
have additional recommendations or change their guidance or
requirements before or after approval; the timing and outcome of
research, development and regulatory review is uncertain; we expect
to need additional funds to advance all of our programs, and you
and others may not agree with the manner we allocate our resources;
our drug candidates may not advance in development or be approved
for marketing; clinical trials and other studies may not proceed at
the time or in the manner expected or at all; enrolling patients in
our ongoing and intended clinical trials is competitive and
challenging; risks related to unexpected or unfavorable new data;
risks related to developing and commercializing drugs; risks
related to relying on partners and other third parties; Arena's and
third parties' intellectual property rights; and satisfactory
resolution of litigation or other disagreements with others.
Additional factors that could cause actual results to differ
materially from those stated or implied by Arena's forward-looking
statements are disclosed in Arena's filings with the Securities and
Exchange Commission. These forward-looking statements represent
Arena's judgment as of the time of this release. Arena disclaims
any intent or obligation to update these forward-looking
statements, other than as may be required under applicable law.
Corporate Contact:
Kevin R.
Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-presented-new-patient-reported-outcomes-data-for-olorinab-at-the-european-society-of-neurogastroenterology--motility-neurogastro-2019-meeting-300913522.html
SOURCE Arena Pharmaceuticals, Inc.